Insulet Corp.

Executive Summary

SELL, Medium conviction. PODD rates a SELL at Medium conviction. The business is executing well in core Omnipod, but the stock still screens above the quant fair value of $126.53, and the key debate has shifted from demand to durability, after FY26 revenue guidance was cut to 20%-22% constant currency because type 2 users are not retaining or utilizing as expected. At $140.53, with the company itself saying 2026 exits at only a mid-teens growth rate and updated 2027 assumptions pushed to Q4, the setup is not good enough yet.

Investment Thesis

The problem is not that Insulet lacks demand. The problem is that the market now has to underwrite a more fragile growth algorithm. Q2 proved the franchise still has force: $802 million of revenue, 22.7% constant-currency growth, 41.5% adjusted EPS growth, 72.9% gross margin, and a customer base up 23%. Yet management still cut full-year guidance because the type 2 cohort was not staying on therapy or using enough in the first 90 days. Ashley McEvoy said, "This is not due to pricing. This isn't due to competition. This isn't due to GLP-1s. This is due to our execution in serving the type 2 community in the first 90 days." That is a useful diagnosis, but it is still a diagnosis of failure in a key expansion vector.

At $140.53, the stock is not expensive on a simple trailing P/E of 26.23x, especially versus the 27.3x peer average. But that framing misses the issue. Investors are not debating whether Omnipod is a good product. They are debating whether Insulet can convert type 2 demand into durable, profitable users at scale. Until that answer is cleaner, the right lens is not peer-average P/E, it is the gap between visible growth and trusted growth. The quant blend lands at $126.53, with the PEG method far lower at $66.73, signaling that quality of growth matters more than the absolute rate.

The bearish case depends on three specific things. First, the U.S. growth engine has slowed enough that FY26 U.S. Omnipod guidance is now only 17%-19%. Second, medium-term visibility has weakened because management deferred the updated 2027 and beyond view to Q4, while saying 2026 exits at only a mid-teens growth rate. Third, cash generation remains underwhelming relative to the growth story, with only $0.1B of FY2025 free cash flow and a Cash Flow Quality score of 39/100.

The counterargument is real: this is a serial beater, with 8 straight quarterly EPS beats, including +12.9%, +19.3%, and +27.2% in the last six reported quarters. That keeps conviction at Medium rather than High on the short side. If retention actions stabilize the type 2 funnel and Q4 restores a credible 2027 framework, the stock can work. Until then, the business looks better than the stock.

Key Metrics

Financial Strength

The balance sheet is acceptable, not a reason to own the stock by itself. Leverage at 1.78x debt/EBITDA and a 2.48x current ratio leave room to keep investing, and operating margin improved to 16.8% in FY2025 from 14.9% the year before. The issue is cash conversion. FY2025 free cash flow was only $0.1B, and the 39/100 cash flow quality score fits that picture. Gross margin is moving in the right direction, but until that starts flowing through to steadier EBITDA and free cash flow, the financial profile remains good enough, not strong enough to pay up for uncertain duration.

Competitive Position

Insulet still has a real moat. Omnipod benefits from a differentiated tubeless form factor, embedded patient behavior, payer access gains, and manufacturing know-how that is showing up in margins. Access expansion of 6.5M lives plus simplified prior auth for about 10M lives strengthens distribution, and international traction, including Omnipod 5 becoming #1 for new users in Australia, shows the model travels. The weak point is not product relevance. It is commercial execution in type 2, where retention, onboarding, and patient targeting now matter as much as winning the initial prescription.

Management & Guidance

Management credibility is mixed but still respectable. On one hand, Insulet has beaten EPS expectations for 8 straight quarters, including 1.66 vs 1.47 in August and 1.42 vs 1.19 in May, which supports confidence in quarter-to-quarter execution. On the other hand, the key change in the latest call was a guidance cut despite strong current demand. McEvoy said, "We now expect 2026 total company revenue growth of 20% to 22% and U.S. Omnipod growth of 17% to 19%." The explanation was candid and company-specific, but investors still need proof that revised customer care, sampling, and compensation changes can fix the first-90-day type 2 dropout problem before giving management full credit for the FY26 and 2027 algorithm.

Bull Case

• Q2 2026 was operationally strong: revenue rose 23.5% reported, 22.7% constant currency, and adjusted EPS increased 41.5% to $1.66.
• Gross margin expanded 320 bps year over year to 72.9%, and management still expects about 100 bps of operating margin expansion in FY26, helped by manufacturing productivity in Acton and Malaysia.
• The customer base grew 23%, global new customer starts were the second highest quarter ever, and international Omnipod is still guided to 30%-32% constant-currency growth for FY26.
• Access keeps improving, with 6.5M lives added and prior authorization simplified for about 10M lives, which supports medium-term penetration.

Bear Case

• FY26 guidance was reduced even after a strong quarter, which matters more than the beat: management now expects 20%-22% total company growth, down because early type 2 retention and utilization were weaker than expected.
• Q2 EBITDA margin was 16.5%, down 370 bps versus Q1, showing that margin progression is not linear even with strong gross margin.
• Cash generation is not yet robust for a company that still needs to invest for growth, with FY2025 free cash flow of only $0.1B on $2.7B of revenue and a Cash Flow Quality score of 39/100.
• Long-range visibility weakened when management deferred updated 2027 and beyond assumptions to Q4, while saying 2026 should exit at only a mid-teens constant-currency growth rate.

Valuation & Price Target

Engine price target $126.53 (-10% vs current), Medium confidence.

• P/E Multiple: $146.33 (28% weight)
• PEG (growth-adjusted): $66.73 (20% weight)
• P/S Multiple: $144.59 (20% weight)
• Quality-adjusted: $140.53 (20% weight)

This call aligns with the quant baseline SELL rather than diverging from it. The valuation blend points to $126.53, with the biggest warning from the PEG-based value of $66.73, which captures that growth quality has slipped after the FY26 cut. Sell-side consensus still leans Buy at 8 buy / 8 hold / 1 sell, but that is low-signal context here. The hard data argue for caution: FY2025 EPS grew only 2.1% to $3.51, free cash flow was just $0.1B, Q2 exposed a real type 2 retention problem, and management pushed the updated 2027 framework out to Q4.

Risk Assessment

Risk score 43/100 (Moderate). The biggest risk to the bearish view is that type 2 retention fixes work quickly, because the underlying franchise is still producing 20%-22% FY26 growth, 72.9% gross margin, and at least 30% adjusted EPS growth.

The Bottom Line

PODD is a SELL. The business is better than the recent stock action suggests, but not yet good enough to dismiss a guidance cut tied to the exact market expansion opportunity that matters most next. The setup can improve quickly if November shows better type 2 retention and Q4 restores a credible 2027 framework, but that evidence is not in hand today. At $140.53, with a quant fair value of $126.53 and growth visibility weaker than it looked a quarter ago, patience is the right stance. A move to Hold or Buy would require proof that U.S. type 2 retention is stabilizing and that mid-teens exit growth is a floor, not the new ceiling.